Today, FDA’s Oncologic Drugs Advisory Committee voted unanimously (12/12) in favor of the use of MRD as an endpoint to support accelerated approval of new therapies for patients with multiple myeloma. This is fantastic news for the hematology community, with the potential to bring life-saving therapies to patients sooner. https://lnkd.in/gkTUhEEq
Adaptive Biotechnologies Corp.
Biotechnology
Seattle, WA 28,602 followers
Every immune system has a story to tell; the key is knowing how to listen.
About us
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases -- such as cancer, autoimmune conditions, and infectious diseases -- are diagnosed and treated. For more information, please visit adaptivebiotech.com.
- Website
-
http://www.adaptivebiotech.com
External link for Adaptive Biotechnologies Corp.
- Industry
- Biotechnology
- Company size
- 501-1,000 employees
- Headquarters
- Seattle, WA
- Type
- Public Company
- Founded
- 2009
- Specialties
- Biotechnology, Research, Diagnostic, and Therapeutics
Locations
-
Primary
Get directions
1551 Eastlake Ave E. Suite 200
Seattle, WA 98102, US
-
Get directions
2 Tower Pl
South San Francisco, California 94080, US
Employees at Adaptive Biotechnologies Corp.
-
Erica Hesse
-
John Alsobrook II, PhD, DABCC, FAACC
-
Theresa Nicoletto, MBA
Rare Disease Sales and Management | Patient Advocacy | Business Development | Product Launch Experiences | Sales Training | Managed Care |…
-
Mary Pat Lancelotta
Biotech and Life Sciences Commercial Executive | Board Member
Updates
-
As June comes to a close, we take a moment to reflect on the significance of Pride Month. It's a time for the LGBTQ+ community to shine and for allies to gain insight into the diverse experiences and challenges faced by its members. At Adaptive, we are dedicated to fostering a strong sense of community and belonging through education, advocacy, and celebrations. Read more: https://lnkd.in/g5RrpcRV
Pride Month at Adaptive: Celebrating Progress and Community
https://www.adaptivebiotech.com
-
Adaptive is proud to participate in this collaborative effort. Through this project we are eager to explore how MRD testing can add insight to the clinical assessment of MGUS and SMM patients, and in particular how testing can reduce or alleviate the ongoing uncertainty that so many patients with these diagnoses face. Together with the Foundation for the National Institutes of Health, industry and academic partners, we aim to transform patient care and improve quality of life. Learn more about our project and its potential impact at fnih.org/MMyeRisk. #MultipleMyeloma #BridgestoBreakthroughs
Today, the FNIH Biomarkers Consortium announces the launch of a significant project to develop and validate blood-based biomarkers for predicting progression to multiple myeloma. This collaborative initiative brings together critical resources and stakeholders from the public sector, the private sector, and academia. By creating less invasive and more accurate prediction methods, we aim to enable earlier treatment and improve patient outcomes. Watch to hear more about the project from investigators Irene Ghobrial, MD, Professor of Medicine, Dana-Farber Cancer Institute, and Bruno Paiva, PhD, Co-director, Flow Cytometry Platform & Monoclonal Gammopathies Research Laboratory, University of Navarra. Learn more at fnih.org/MMyeRisk #FNIH #BridgesToBreakthroughs #Biomarkers #BiomarkersConsortium #MultipleMyeloma #CancerResearch Pfizer Regeneron AbbVie
-
Adapters are gearing up for Obliteride 2024 through a packed schedule of team training rides! We're proud to support the Fred Hutch to #CureCancerFaster.
-
-
Three new Adaptive manuscripts shed light on the complex relationship between T-cell responses and various exposures, offering new avenues for research and clinical applications. Learn more: https://lnkd.in/exxgHGrd
-
At #ASCO24 and #EHA2024 new data and real-world evidence using Adaptive’s clonoSEQ® for MRD assessment will be presented across a range of hematologic cancers. https://lnkd.in/gJuPg99B FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Review the FDA-cleared uses of clonoSEQ: https://rb.gy/8tju9y
-
-
Adaptive Biotechnologies Corp. reposted this
Visit booth 33087 at #ASCO24 to discuss #MRD assessment in lymphoid malignancies with our team. #mmsm #leusm clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: https://rb.gy/8tju9y
-
-
Check out this excellent tool from NCODA: the PQI In Action for Minimal Residual Disease Testing in Multiple Myeloma. Created with Florida Cancer Specialists & Research Institute and Rocky Mountain Cancer Centers, this easy-to-use clinical resource guide breaks down how medical teams can use clonoSEQ to optimize patient outcomes. https://lnkd.in/eNRhfyHN FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Review the FDA-cleared uses of clonoSEQ: https://rb.gy/8tju9y
pqi_clonoSEQ_digital.pdf
ncoda.org